File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1160/TH09-05-0336
- Scopus: eid_2-s2.0-77954375976
- PMID: 20352151
- WOS: WOS:000280298300003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Stem cells for myocardial repair
Title | Stem cells for myocardial repair | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Keywords | Cardiology Ischaemic heart disease Stem cells | ||||||
Issue Date | 2010 | ||||||
Publisher | Schattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com | ||||||
Citation | Thrombosis And Haemostasis, 2010, v. 104 n. 1, p. 6-12 How to Cite? | ||||||
Abstract | There is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy. © Schattauer 2010. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/125015 | ||||||
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 1.248 | ||||||
ISI Accession Number ID |
Funding Information: This work was supported by grants the Hong Kong Research Grant Council General Research Fund (HKU 763306M, HKU 7747/08M to C.W.S. and H.F.T.) and the CC Wong Stem Cell Fund (to H.F.T.). | ||||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Siu, CW | en_HK |
dc.contributor.author | Liao, SY | en_HK |
dc.contributor.author | Liu, Y | en_HK |
dc.contributor.author | Lian, Q | en_HK |
dc.contributor.author | Tse, HF | en_HK |
dc.date.accessioned | 2010-10-31T11:06:43Z | - |
dc.date.available | 2010-10-31T11:06:43Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | Thrombosis And Haemostasis, 2010, v. 104 n. 1, p. 6-12 | en_HK |
dc.identifier.issn | 0340-6245 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/125015 | - |
dc.description.abstract | There is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy. © Schattauer 2010. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Schattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com | en_HK |
dc.relation.ispartof | Thrombosis and Haemostasis | en_HK |
dc.subject | Cardiology | en_HK |
dc.subject | Ischaemic heart disease | en_HK |
dc.subject | Stem cells | en_HK |
dc.subject.mesh | Bone Marrow Cells - pathology | - |
dc.subject.mesh | Myoblasts, Skeletal - pathology | - |
dc.subject.mesh | Myocardial Infarction - pathology - physiopathology - therapy | - |
dc.subject.mesh | Myocardium - metabolism - pathology | - |
dc.subject.mesh | Stem Cell Transplantation | - |
dc.title | Stem cells for myocardial repair | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0340-6245&volume=104&issue=1&spage=6&epage=12&date=2010&atitle=Stem+cells+for+myocardial+repair | en_HK |
dc.identifier.email | Siu, CW:cwdsiu@hkucc.hku.hk | en_HK |
dc.identifier.email | Lian, Q:qzlian@hkucc.hku.hk | en_HK |
dc.identifier.email | Tse, HF:hftse@hkucc.hku.hk | en_HK |
dc.identifier.authority | Siu, CW=rp00534 | en_HK |
dc.identifier.authority | Lian, Q=rp00267 | en_HK |
dc.identifier.authority | Tse, HF=rp00428 | en_HK |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1160/TH09-05-0336 | en_HK |
dc.identifier.pmid | 20352151 | - |
dc.identifier.scopus | eid_2-s2.0-77954375976 | en_HK |
dc.identifier.hkuros | 173516 | en_HK |
dc.identifier.hkuros | 182864 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77954375976&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 104 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 6 | en_HK |
dc.identifier.epage | 12 | en_HK |
dc.identifier.isi | WOS:000280298300003 | - |
dc.publisher.place | Germany | en_HK |
dc.identifier.scopusauthorid | Siu, CW=7006550690 | en_HK |
dc.identifier.scopusauthorid | Liao, SY=22433820700 | en_HK |
dc.identifier.scopusauthorid | Liu, Y=36071722500 | en_HK |
dc.identifier.scopusauthorid | Lian, Q=7003399023 | en_HK |
dc.identifier.scopusauthorid | Tse, HF=7006070805 | en_HK |
dc.identifier.issnl | 0340-6245 | - |